Alvotech

About

Alvotech specializes in making biosimilars to create biologic medicines.

Reykjavík,Gullbringusysla,Iceland
501 - 1000
http://www.alvotech.com

Highlights

Details

Last Funding Type: Post-IPO Debt
Last Funding Money Raised: $70M
Industries: Biotechnology,Life Science,Pharmaceutical
Founded date: Jan 1, 2013
Number Of Employee: 501 - 1000
Operating Status: Active
Stock Symbol: nasdaq:ALVO
Legal Name: ALVOTECH ehf.
Also Known As: Alvotech Biosimilars

Alvotech is a fully integrated specialty biopharmaceutical company focused exclusively on the development and manufacture of high-quality biosimilar medicines.

The company's goal is to improve patients' health and quality of life around the world by increasing access to effective therapies for various ailments.

Alvotech was established on January 1, 2013 by Róbert Wessman in Reykjavík, Gullbringusysla.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

7

$657M

Alvotech has raised a total of $657M in funding over 2 rounds. Their latest funding was raised on Jan 23, 2023 from a Post-IPO Equity round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Jan 23, 2023	Post-IPO Equity	$137M	—	—	—	Detail
Dec 16, 2022	Post-IPO Debt	$70M	—	—	—	Detail
Jun 16, 2022	IPO	—	—	—	—	Detail
Mar 15, 2021	Series Unknown	$35M	—	—	—	Detail
Oct 27, 2020	Series Unknown	$65M	5	—	—	Detail

Investors

Number of Lead Investors

Number of Investors

1

6

Alvotech is funded by 6 investors. Fuji Pharma and Alvogen are the most recent investors.

Investor Name	Lead Investor	Funding Round
Fuji Pharma	Yes	Corporate Round
Alvogen	—	Series Unknown
Athos Capital	—	Series Unknown
Aztiq Pharma	—	Series Unknown
Baxter Ventures	—	Series Unknown
Shinhan Capital	—	Series Unknown